Evidence map›Paper›PMID 37111691›Full record

ArticlePharmaceutics2023

Synergistic Encapsulation of Paclitaxel and Sorafenib by Methoxy Poly(Ethylene Glycol)-

Chae Eun Jin, Moon Sup Yoon, Min Jeong Jo, Seo Yeon Kim, Jae Min Lee, Su Jeong Kang, Chun-Woong Park, Jin-Seok Kim, Dae Hwan Shin

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 21 citations in OpenAlex.

  1. [Exploration and application of nanotechnology in precision transarterial chemoembolization for hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chae Eun JinCollege of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
Moon Sup YoonCollege of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
Min Jeong JoCollege of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
Seo Yeon KimCollege of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
Jae Min LeeCollege of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
Su Jeong KangCollege of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
Chun-Woong ParkCollege of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
Jin-Seok KimDrug Information Research Institute (DIRI), College of Pharmacy, Sookmyung Women's University, Cheongpa-ro 47-gil 100, Yongsan-gu, Seoul 04310, Republic of Korea.
Dae Hwan ShinCollege of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea.
Chungbuk National University · KRSookmyung Women's University · KR

Funding

"Regional Innovation Strategy (RIS)" through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (MOE) 2021RIS-001the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, grant number NRF-2022R1C1C1007107This research was supported by a National Research Foundation (NRF) of Korea Grant funded by the Korean government (MSIP) No. MRC2017R1A5A2015541
6 · The paper itself

Abstract

Ovarian cancer has a high mortality rate due to difficult detection at an early stage. It is necessary to develop a novel anticancer treatment that demonstrates improved efficacy while reducing toxicity. Here, using the freeze-drying method, micelles encapsulating paclitaxel (PTX) and sorafenib (SRF) with various polymers were prepared, and the optimal polymer (mPEG-

Indexed as

antitumorcombination therapymicellemPEG-b-PCLovarian cancerpaclitaxelpharmacokineticssorafenib

Identifiers

PMID37111691
PMCPMC10146360
OpenAlexW4363651526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.